SHAROKY MELVIN MD

Director SHAROKY MELVIN MD sold 20,000 shares of INSM at $205.01 on 2025-12-05 for $4,100,200.00

Director SHAROKY MELVIN MD sold 20,000 shares at $205.01, reducing holdings by 7.6% to 243,948 shares. The sale occurred near the 52-week high ($211.41), with the stock currently trading 8.2% below that peak at $194.17. At this specific ticker, the director's prior three sales (Sept 2025, Aug 2025, and Aug 2025) each posted positive 90-day returns of +11.6%, +55.7%, and +57.8% respectively, indicating these prior sales were poorly timed relative to subsequent price appreciation. INSM remains an unprofitable company with full-year net income of $-370,021,000.00, though the business grew revenue 19.2% year-over-year to $142,342,000.00 in the latest quarter. The current sale at elevated price levels warrants attention given the company's ongoing profitability challenges and the director's historical pattern of selling ahead of rallies rather than declines.

Director Sharoky Melvin MD sold 10,000 shares of INSM at $145.39; stock near 52-week high of $147.20.

Director Sharoky Melvin MD sold 10,000 shares (10.0K shares) at $145.39, reducing his holdings by 3.7% to 262,675 shares. The sale occurred near the upper end of the 52-week trading range ($64.81–$147.20), with the stock only 2.8% below its 52-week high. Across his same-ticker history at INSM, Melvin's prior trades show mixed near-term outcomes: a prior sell on 2025-08-12 showed a 30-day return of +19.9%, and his two buys in May 2023 had 90-day returns of +16.3%. In broader context, INSM remains unprofitable with a net loss of $-321.7M over its most recent full fiscal year, though annual revenue grew 19.2%, and the company carries a market cap of $30.3B. The sale at elevated pricing levels is a factual transaction without clear forward-looking signal based on the available data.

Director SHAROKY MELVIN MD sold 10,000 INSM shares at $129.50 on 2025-08-20, leaving holdings at 274.5K shares post-transaction.

On 2025-08-20, director SHAROKY MELVIN MD sold 10,000 shares of INSM at $129.50, reducing holdings from 284.5K shares to 274.5K shares. The timing follows a dramatic price rally: the stock has gained 28.8% over the prior 30 days and 96.4% over the prior 90 days, now trading at $132.60, which matches the 52-week high. Notably, this is the second sale in 8 days—the insider sold 10,000 shares again on 2025-08-12, also during this steep uptrend. Across his same-ticker history at INSM, the prior 2025-08-12 sell occurred during a period of strong momentum that remains unmeasured (90-day outcome not yet available), while his earlier 2023 buys both achieved positive 90-day returns. The company remains unprofitable (net income of $-321.7M in its most recent full fiscal year) despite 19.2% annual revenue growth, and the market cap of $28.0B implies a valuation tied to forward expectations rather than current profitability. This back-to-back selling during a near-52-week-high rally warrants attention as a potential signal of how the director assesses current valuation relative to intrinsic value.

Director Sharoky Melvin MD sells 10,000 INSM shares (59.4% of holdings) at $121.58; stock now at $127.75

SHAROKY MELVIN MD sold 10,000 shares (10.0K shares) of INSMED Inc (INSM) at $121.58 on 2025-08-12, reducing his holdings from 16,847 shares (16.8K shares) to 6,847 shares (6.8K shares)—a substantial reduction of 59.4% of his pre-transaction position. The stock has since appreciated to $127.75 (current price), trading at its 52-week high and up 24.2% over the past 30 days and 87.5% over the past 90 days. In his cross-ticker track record, Melvin's 2 prior buys averaged a 90-day return of 16.3% with a 100% win rate; his same-ticker history at INSM shows 2 prior buys (both on 2023-05-15) that each delivered 16.3% returns over 90 days, establishing a pattern of well-timed entry timing at this ticker. Against this backdrop of strong recent price momentum and Melvin's historical pattern of well-timed buys, the sale of a 59.4% stake at $121.58—ahead of the current $127.75 level and during a period of accelerating gains—diverges from his buy timing discipline and warrants investor scrutiny of the underlying rationale.